Doximity initiated with a Market Perform at BMO Capital

BMO Capital initiated coverage of Doximity (DOCS) with a Market Perform rating and $55 price target Doximity’s strong clinician engagement through its social and workflow platform enhances its appeal as a marketing tool for pharmaceutical companies, the analyst tells investors in a research note. While growth opportunities remain through user expansion and monetization, the current valuation suggests much of this potential is already reflected in the share price, BMO says.